Processa Pharmaceuticals
Logotype for Processa Pharmaceuticals Inc

Processa Pharmaceuticals (PCSA) investor relations material

Processa Pharmaceuticals Company presentation summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Processa Pharmaceuticals Inc
Company presentation summary13 Nov, 2026

Transaction and capital

  • Vidya’s equity was exchanged for common stock and newly created Series A non-voting convertible preferred stock in a sign-and-close reverse merger.

  • A concurrent $200M PIPE is designated for pipeline advancement, working capital and general corporate purposes; pro forma runway is expected into 2029, through multiple clinical milestones.

  • Expected capitalization after Series A conversion: 2.8M common shares plus 306.6M as-converted preferred shares, totaling 309.4M; subject to stockholder approval and beneficial ownership limits.

VT7208

  • Potentially best-in-class, once-daily oral BTK inhibitor with preclinical potency, peripheral and CNS target engagement, and consistent efficacy across disease models.

  • Phase 1 showed favorable safety and tolerability across evaluated doses, with no dose-limiting toxicities, serious adverse events, treatment-related discontinuations, liver safety signal or bleeding-related events.

  • Median half-life was ~6 hours, supporting once-daily dosing; exposure increased near dose-proportionally and BTK occupancy remained ≥95% for 48 hours after the last dose.

  • Phase 2 initiation and proof-of-concept data targeted: food allergy H2 2026 and H2 2027; CSU H2 2026 and H1 2028; relapsing MS H1 2027 and H2 2028.

Oral FcRn program

  • Research collaboration and exclusive option with Generian Pharmaceuticals covers a macrocyclic peptide against the clinically validated FcRn target; work is in lead optimization through development-candidate nomination.

  • FcRn blockade directs pathogenic IgG, including autoantibodies, to degradation; the mechanism may address IgG-driven diseases including MG, CIDP, ITP and wAIHA.

  • VYVGART generated $4.15B in 2025 global net sales, up 90% vs. 2024; development-candidate nomination for the oral program is targeted for 2H 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Processa Pharmaceuticals earnings date

Logotype for Processa Pharmaceuticals Inc
9th Annual Evercore ISI HealthCONx Conference2 Dec, 2026
Processa Pharmaceuticals
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Processa Pharmaceuticals earnings date

Logotype for Processa Pharmaceuticals Inc
9th Annual Evercore ISI HealthCONx Conference2 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for patients with unmet medical needs. The company is engaged in the research and development of drug candidates aimed at addressing serious conditions across multiple therapeutic areas, including oncology and infectious diseases. Processa Pharmaceuticals' approach involves advancing its drug candidates through clinical trials to provide safer and more effective therapies. Its pipeline targets conditions where current treatment options may be limited or inadequate, aiming to improve patient outcomes and quality of life. The company is headquartered in Hanover, Maryland, and its shares are listed on the NASDAQ.